Baseline Evaluation (Pre-treatment)

Patient Name ______________________________________
 
Evaluation Date _________________________

History

If you answer YES to any of the following questions, then this patient should not be treated.

No Yes
Has the patient had ascites?
 
Top Top
Has the patient had encephalopathy?
 
Top Top
Has the patient had variceal bleeding?
 
Top Top
Does the patient have a history of significant or unstable cardiac disease?
 
Top Top
Has the patient ever had severe depression?
 
Top Top
Has the patient ever been hospitalized for a psychiatric disorder?
 
Top Top
Has the patient ever felt suicidal or had a suicide attempt?
 
Top Top
Does the patient have thalassemia or any blood disorders?
(e.g. hemoglobinopathy, hemolytic anemia)?
 
Top Top
Does the patient have Wilson's disease, hemochromatosis, hepatitis B,
autoimmune hepatitis, PBC, PSC, alcoholic liver disease or other
cause of chronic liver disease?
 
Top Top
Is the patient pregnant, planning to become pregnant or breast feeding?
 
Top Top
Has the patient had a transplant (e.g. liver, kidney, bone marrow, heart)?
 
Top Top
Does the patient have normal Alanine Aminotransferases?
 
Top Top
Does patient have hypersensitivity to Interferon or Ribavirin?
 
Top Top

 

Pre-Treatment Labs

Date   _________________________
 
WBC (x 1000)
 
[ __ __.__ ]
Neutrophil count (%)
 
[ __ __ ] OR (x 1000) [ __ .__ __ ]
Hemoglobin (g/dl)
 
[ __ __.__ ]
Platelets (x 1000)
 
[ __ __ __ ]
Reticulocyte count (%)
 
[ __ .__ __ ] OR (10 9/l) [ __ __ . __ ]
AST (IU)
 
[ __ __ __ ]
ALT (IU)
 
[ __ __ __ ]
Alkaline Phosphatase (IU)
 
[ __ __ __ ]
Total Bilirubin (mg/dl)
 
[ __.__ ]
Serum Albumin (g/dl)
 
[ __.__ ]
Prothrombin Time (seconds)
 
[ __ __.__ ]
Prothrombin Time INR
 
[ __.__ ]
Glucose (mg/dl)
 
[ __ __ __ ]
BUN (mg/dl)
 
[ __ __ ]
Serum Creatinine
 
[ __ .__ ]
TSH
 
[ __ __.__ ]
HCV-RNA Genotyping (optional)
 
[ _________ ]
  Positive Negative
HCV-RNA PCR
 
Top Top
Urine or Serum Pregnancy Test
 
Top Top

 

Eligible Treatment Candidates

If you answer YES to all of the following questions, then the patient is a good candidate for treatment.

No Yes
HCV-RNA positive
 
Top Top
Hemoglobin >= 12 g/dl for females or >= 13 g/dl for males
 
Top Top
WBC within normal limits
 
Top Top
Neutrophil Count within normal limits
 
Top Top
Platelets >= 70,000/mm3
 
Top Top
Prothrombin time <= 3 seconds prolonged or INR ratio <= 1.5
 
Top Top
Serum Albumin >= 3.0 g/dl or within 20% of lower limit of normal
 
Top Top
Serum Creatinine <= 1.4 mg/dl
 
Top Top
TSH within normal limits
 
Top Top
Total Bilirubin within normal limits
(unless Gilbert's disease is present, then indirect bilirubin should be <= 3.0 mg/dl)
 
Top Top
ANA negative (<= 1:160)
 
Top Top
Females of childbearing potential and males are willing to use effective contraception during treatment period and for 6 months post treatment.
 
Top Top

 
 
**Eligible Treatment Candidates, but these patients must be treated with Extreme Caution:
  • Patients with history of Pulmonary infiltrates or impairment
     
  • Patients with Creatinine Clearance < 50 ml/min
     
  • Patients with Diabetes Mellitus

 
 

Treatment Dosages and Administration

Rebetron
Body Weight Rebetol Capsules Intron A
<= 75 kg 2 capsules qam po
3 capsules qpm po
3 million units SQ TIW
> 75 kg 3 capsules qam po
3 capsules qpm po
3 million units SQ TIW

 
Length of Treatment:
Treatment Naïve: Genotype 1 should be treated x 12 months
Non genotype 1 should be treated x 6 months
Treatment Relapsers: Genotype 1 should be treated for 6 months
Non genotype 1 should be treated for 6 months

 
Infergen
Treatment Naïve: 9 mcg SQ TIW x 6 months
Previously Treated: 15 mcg SQ TIW x 6 months

 
 
Dose Reduction:   Can include either interferon or ribavirin.or both drugs For hemoglobin abnormalities you can just reduce the ribavirin to half dose, for other abnormalities (except psychiatric or emotional) reduce interfeon to half dose. If using combination therapy reduce both drugs for psychiatric or emotional abnormalities.

Top

 
©Copyright 2000   University of Washington. All rights reserved